GNLX
GNLX
NASDAQ · Biotechnology

Genelux Corp

$3.01
+0.11 (+3.79%)
As of Jun 30, 10:33 PM ET ·
Financial Highlights (FY 2026)
Revenue
8.7K
Net Income
-37,722,024
Gross Margin
Profit Margin
-401,812.5%
Rev Growth
-91.0%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 58.3% 58.3%
Operating Margin -415,175.0% -373,659.5% -22.4% -22.6%
Profit Margin -401,812.5% -381,721.9% -22.1% -17.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 8.7K 97.3K 62.40M 61.85M
Gross Profit 36.39M 36.07M
Operating Income -36,219,867 -363,410,036 -14,003,493 -13,961,219
Net Income -37,722,024 -378,481,846 -13,759,336 -10,609,098
Gross Margin 58.3% 58.3%
Operating Margin -415,175.0% -373,659.5% -22.4% -22.6%
Profit Margin -401,812.5% -381,721.9% -22.1% -17.2%
Rev Growth -91.0% -91.0% +12.2% +11.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 27.99M 31.26M
Total Equity 51.92M 51.92M
D/E Ratio 0.54 0.60
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -38,686,123 -409,719,251 -15,040,886 -15,866,697
Free Cash Flow -13,384,851 -9,996,517